Antiphospholipid Antibody Syndrome Completed Phase 4 Trials for Rivaroxaban (DB06228)

IndicationStatusPhase
DBCOND0029330 (Antiphospholipid Antibody Syndrome)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02116036Rivaroxaban for Antiphospholipid Antibody SyndromeOther